> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves Ridgeback Ebanga Ebolavirus Treatment
- URL: https://www.fdaweb.com/fda-approves-ridgeback-ebanga-ebolavirus-treatment/
- Published: 2021-01-04T12:00:00.000Z
- Updated: 2026-09-14T16:41:07.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148356

FDA has approved Ridgeback Biotherapeutics’ Ebanga (ansuvimab-zykl), a human monoclonal antibody, to treat *Zaire ebolavirus* infection in adults and children. An agency [notice](https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-treatment-ebola-virus?ref=fdaweb.com) says Ebanga blocks binding of the virus to the cell receptor, preventing its entry into the cell.

The agency says that *Zaire ebolavirus* is one of four *Ebolavirus* species that can cause a potentially fatal human disease.

Ebanga’s safety and efficacy were evaluated in the multi-center PALM trial in which 174 participants with confirmed Ebolavirus infection received Ebanga intravenously as a single 50 mg/kg infusion and 168 participants received an investigational control. The primary endpoint was 28-day mortality. Of the 174 patients who received Ebanga, 35.1% died after 28 days, compared to 49.4% of those who received the investigational control.